RFVIIa, rFVIIa + TXA ( DrugBank: rFVIIa )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
288	自己免疫性後天性凝固因子欠乏症	1

288. 自己免疫性後天性凝固因子欠乏症

---

臨床試験数 : 206 /  薬物数 : 231 - (DrugBank : 28) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 21

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01800435 (ClinicalTrials.gov)	October 2011	15/2/2013	A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor	Whole Blood Clot Stability and Thrombin Generating Capacity Following Treatment With Bypassing Agents (BPA) With and Without and Tranexamic Acid (TXA) in Haemophilia A Patients With inhibitor-an In-vivo Prospective Crossover Study	Hereditary Factor VIII Deficiency Disease With Inhibitor	Drug: aPCC, aPCC + TXA;Drug: rFVIIa, rFVIIa + TXA	Oslo University Hospital	NULL	Completed	18 Years	65 Years	Male	6	Phase 4	Norway